🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📢Have you listened to🎙️2? It focuses on the #Gastric CDHI Multicenter Consortium & features Ophir Gilad one of the consortium leads. ➡️Learn more about their current work & vision for the future by listening to the 🎙️& reading the 📜written by our comms cttee member

12% of #patients w/ #breastcancer >65 yo had a PGV on comprehensive multigene panel #germline #genetictesting onlinelibrary.wiley.com/doi/10.1002/js… Journal of Surgical Oncology Wiley in research Only ~55% of #patients >65 yo w/ #TNBC #breastcancer received #germlinetesting, though all w/ TNBC are recommended

11% of #patients w/ #SCLC have PGVs on #germline #genetictesting per systematic review & meta-analysis, #patients with P/LP variants in DNA damage response and repair genes have a trend for better overall survival. Similar to >14% #patients w/ #NSCLC having PGVs w/

🧬 Save the date! ➡️Join us for Hereditary Live on June 12 | 6PM ET / 3PM PT – a global forum where clinicians share complex cases & get real-time expert input. 🗓️ Add to calendar 👉 evt.to/eueseiugw 📥 Submit a case 👉 surveymonkey.com/r/HereditaryLI… #HereditaryGICancer

🎧 Don’t miss the final episode of our research collaboration podcast series! 👉 tinyurl.com/3dabbnw7 Emma Keel (Emma Keel (she/her)) chats with Melyssa Aronson (Melyssa Aronson ) & Lucie Stengs from the IRRDC about their global work on rare genetic disorders like #CMMRD. From

Only 39% of #patients w/ #pancreaticcancer offered #germline #genetictesting post National Comprehensive Cancer Network (NCCN) #universal recommendation, vs. 34% pre-universal recommendation, per #DrDerkKlatte et al. "...this study underscores the #underutilization of #germline GT despite guideline recommendations

With Joe Biden's diagnosis of #metastatic #prostatecancer I hope his physicians have already provided him #germline #genetictesting & #somatic #tumorsequencing so he derives the full benefit of the #precisiontherapies made possible by the #BidenCancerMoonshot he & Dr. Jill Biden

"Ultimately, we need to implement #universal #somatic and #germlinetesting in all #patients with #cancer if we are serious about beating most cancer types. " Vivek Subbiah, MD et al. Nature Medicine c/w ascopubs.org/doi/10.1200/PO… JCO Precision Oncology ASCO Invitae Labcorp

1/Welcome to #CGAIGCJS Tweetorial on “Neoplasia Detection Through Colonic Surveillance Among Young Individuals With MSH6/PMS2-Associated #LynchSyndrome” by CGA-IGC communications committee member Dan Li Full article in AJG - The American Journal of Gastroenterology at DOI: 10.14309/ajg.0000000000003369

4/🔎Study findings 👉 285 individuals with MSH6/PMS2-associated LS (161 [56%] MSH6; 124 [44%] PMS2) 👉 125 (44%) had neoplasia detected, including 53 (19%) with CRC (32 [20%] MSH6; 21 [17%] PMS2), with a median age at CRC diagnosis of 38 years (40.5 years for MSH6 vs 36 years for

7/ Thank you & tune in every month for #CGAIGC Communications Committee tweetorials on publications that impact our #HereditaryGICancer patients ➡️Want a curated Journal Scan for #HereditaryGICancer delivered to your inbox every month? ➡️Become a CGA-IGC Member here

🔊 Interested in volunteering and giving back to the #HereditaryGICancer community? 🚨The #CGAIGC Call for Nominations is now open! ➡️Nominate yourself or a colleague for one of our working committees. Only self nominations are accepted for Executive Council! 📌Help shape

Just in time for #ASCO25 ASCO "The #evidence is becoming irrefutable and catalyzing a call for #universal #germline #genetictesting for all #patients with any #cancer type for the purposes of getting those #patients on the right #therapies." "All #patients with #cancer should

📢May is National Asian American and Pacific Islander (AAPI) Heritage Month—a time to highlight experiences of the AAPI community. ➡️In recognition of this month, Chandrika Kurpad, MS, LCGC a member of our Communications Committee, authored a thoughtful blog post titled "Understanding Barriers to

📢Join us for an informative webinar on the advancements in #cancer prevention for individuals with #LynchSyndrome. 📅 Wednesday, June 18th 🕛 12 PM ET / 9 AM PT ➡️Register here 👉tinyurl.com/e5t7krtt Expert speakers Holli Loomans-Kropp, PhD, MPH, & Ajay Bansal , MD,

For decades, #genetictesting was rationed—reserved only for #patients who fit narrow, outdated clinical guidelines. But what happens when those guidelines leave countless people at risk? In this episode, #clinicalgeneticist and medical innovator Dr. Ed Esplin of LabCorp Genetics,

This is an excellent example of the critical clinical need for #universal #germlinetesting of all #patients w/ #cancer, as virtually all #cancer types are potentially associated w/ a #cancersyndrome, & we in the medical community cannot afford to miss a single #patient for lack

"Implementation of #pancancer #universal #germlinetesting in an ethnically diverse and rural #community #oncology practice." (NCT05416710) Prospective #patient cohort, 30% AA, 27% w/ annual income < $25,000, w/ #breast, #colorectal, #lung, #headneck, #prostatecancer, among

"#Genetictesting of an #unselected #gastriccancer cohort: Uncovering #germline mutations and their #clinical #implications." #Germline PVs in 8.7%, including: #BRCA2 (2.9%), #BARD1 (1.4%), #MSH2 (1.4%), #MSH6 (2.9%). c/w link.springer.com/article/10.100… PVs in 17%, Pedro Uson Junior, MD et al.